Boston Scientific has completed the acquisition of US medical technology firm EndoChoice Holdings for about $210m.
Boston Scientific paid $8.00 per EndoChoice share.
Based near Atlanta of Georgia, EndoChoice develops and commercializes infection control products, pathology services and single-use devices for specialists to treat a range of gastrointestinal (GI) conditions.
With around 2,500 customers in the US, the company produces single-use devices such as resection and retrieval devices, needles, graspers and infection control kits.
EndoChoice produces devices such as band ligators, biopsy forceps, bipolar probes, bite blocks, metal stents and others.
It also offers imaging solutions, including Fuse endoscopy systems, monitors, carts, suction pumps and scope services.
The deal enables Boston Scientific to provide expanded GI services and devices for physicians, hospitals and ambulatory surgery centers.
Boston Scientific endoscopy president and senior vice president Art Butcher said: "We are excited to provide physicians more comprehensive solutions to help assess, diagnose and treat patients with GI conditions.
“Boston Scientific is a leader in the field of endoscopy and we are committed to providing innovative products and services to meet the changing and growing needs within the field."
Earlier this month, Boston Scientific acquired tissue retractor system from California-based LumenR for an undisclosed sum.
The LumenR tissue retractor system is currently being developed for use in endoscopic resection of lesions in the colon, esophagus or stomach.
Image: Boston Scientific's corporate headquarters in Marlborough, Massachusetts. Photo: courtesy of Boston Scientific Corporation.